comprehensive
Previous article:
In age of alternative facts, a scholarly course on calling out crap
Next article: JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc
Next article: JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc
hotspot
focus
-
Insitro, AI biotech unicorn, brings cash, new research to JPM 2024
2025-10-01 21:23 -
Kidney transplant patients stopped immunosuppressants in trial
2025-10-01 21:02 -
J&J to buy cancer drug developer Ambrx Biopharma
2025-10-01 20:15 -
Readout Newsletter: Medeor's stem cell study, Moderna's stock dip
2025-10-01 20:14 -
Readout LOUD podcast: ESMO highlights & Roivant's big deal
2025-10-01 19:59 -
What is microchimerism and how does it affect maternal health?
2025-10-01 19:37